Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

482
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
482
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reviewer Comment on Martineau et al. "Barriers to Clinical Care in Frontotemporal Dementia and Related Disorders: A Cross-Sectional Survey of Patients and Caregivers' Journey in the Canadian Healthcare System".

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same author

Longevity and cognitive resilience in a Colombian family carrying the <i>APOE</i> ε2 variant.

Journal of Alzheimer's disease : JAD·2026
Same author

Impact of "Kids' Court" on traffic infraction recidivism in Dar es Salaam: A novel approach to a troublesome problem.

Injury·2026
Same author

Phenotypic diversity of frontotemporal lobar degeneration in two novel GRN variants from Colombia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

The exposome of brain aging across 34 countries.

Nature medicine·2026
Same author

Plasma extracellular vesicles from APOE3 Christchurch carriers display a protective phenotype in early stages of autosomal dominant Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Related Experiment Video

Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

7.3K

Technology and Dementia Preconference.

Juliana Moreno Rada1,2,3,4, Luisa María Zapata Saldarriaga1,2,3,4, Elkin Garcia-Cifuentes4

  • 1Universidad de Antioquia, Medellín, Antioquia, Colombia.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 23, 2025
PubMed
Summary

Electroencephalography (EEG) and dual-task (DT) paradigms effectively identified preclinical Autosomal-Dominant Alzheimer's Disease (ADAD) carriers. These non-invasive biomarkers show promise for early detection in individuals with the PSEN1-E280A variant.

More Related Videos

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.3K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

Related Experiment Videos

Last Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

7.3K
The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.3K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

Area of Science:

  • Neuroscience
  • Biomarker Development
  • Genetics

Background:

  • Colombia has the largest known Autosomal-Dominant Alzheimer's Disease (ADAD) kindred, linked to the PSEN1-E280A genetic variant.
  • Electroencephalography (EEG) is an underutilized biomarker for understanding brain function and electrophysiological changes in ADAD.
  • Dual-task (DT) paradigms, especially during motor tasks, are valuable for detecting cognitive impairments in neurodegenerative diseases.

Purpose of the Study:

  • To investigate the utility of EEG combined with DT paradigms as biomarkers for identifying preclinical ADAD.
  • To differentiate between asymptomatic carriers and non-carriers of the PSEN1-E280A variant using EEG-based DT measures.
  • To establish the feasibility of non-invasive, portable tools for early ADAD detection.

Main Methods:

  • EEG data were collected from asymptomatic PSEN1-E280A carriers (n=37) and non-carriers (n=42) during single-task and dual-task (motor-cognitive) conditions.
  • Dual-task cost (DTC) was calculated using spectral and neural dynamics features from frontal and central EEG signals.
  • Statistical analysis involved Cohen's-D effect size and Mann-Whitney U-tests to compare groups.

Main Results:

  • Significant effect sizes were observed in various EEG frequency bands (Beta, Theta, Alpha) and regions (frontal, central) during specific DT tasks (DTS7, DTS1, DTAN).
  • Entropy in Beta1/Beta3 bands (frontal) and relative power in Beta2 (C4) showed notable differences.
  • Theta and Alpha2 modulations in frontal regions during DTS7 were also significant.

Conclusions:

  • The experimental approach successfully extracted EEG information differentiating PSEN1-E280A carriers from non-carriers.
  • DTC values in alpha and beta bands, particularly in frontal and central regions, indicated sensitivity to preclinical cognitive and motor differences.
  • This EEG and DT paradigm offers a promising, non-invasive tool for early ADAD carrier identification.